These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 27115835)

  • 41. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
    Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
    Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phenylpyrazalopyrimidines as Tyrosine Kinase Inhibitors: Synthesis, Antiproliferative Activity, and Molecular Simulations.
    Chhikara BS; Ashraf S; Mozaffari S; St Jeans N; Mandal D; Tiwari RK; Ul-Haq Z; Parang K
    Molecules; 2020 May; 25(9):. PubMed ID: 32370213
    [No Abstract]   [Full Text] [Related]  

  • 43. Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.
    Kruewel T; Schenone S; Radi M; Maga G; Rohrbeck A; Botta M; Borlak J
    PLoS One; 2010 Nov; 5(11):e14143. PubMed ID: 21152443
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis, anticancer activity, toxicity evaluation and molecular docking studies of novel phenylaminopyrimidine-(thio)urea hybrids as potential kinase inhibitors.
    Türe A; Kahraman DC; Cetin-Atalay R; Helvacıoğlu S; Charehsaz M; Küçükgüzel İ
    Comput Biol Chem; 2019 Feb; 78():227-241. PubMed ID: 30579980
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7.
    Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM
    Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimization of WZ4003 as NUAK inhibitors against human colorectal cancer.
    Yang H; Wang X; Wang C; Yin F; Qu L; Shi C; Zhao J; Li S; Ji L; Peng W; Luo H; Cheng M; Kong L
    Eur J Med Chem; 2021 Jan; 210():113080. PubMed ID: 33310286
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: Synthesis, anticancer, antimicrobial evaluation and computational studies.
    Othman IMM; Alamshany ZM; Tashkandi NY; Gad-Elkareem MAM; Anwar MM; Nossier ES
    Bioorg Chem; 2021 Sep; 114():105078. PubMed ID: 34161878
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment.
    Cui Z; Chen S; Wang Y; Gao C; Chen Y; Tan C; Jiang Y
    Eur J Med Chem; 2017 Aug; 136():372-381. PubMed ID: 28525838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
    Ali S; Heathcote DA; Kroll SH; Jogalekar AS; Scheiper B; Patel H; Brackow J; Siwicka A; Fuchter MJ; Periyasamy M; Tolhurst RS; Kanneganti SK; Snyder JP; Liotta DC; Aboagye EO; Barrett AG; Coombes RC
    Cancer Res; 2009 Aug; 69(15):6208-15. PubMed ID: 19638587
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.
    Shi C; Wang Q; Liao X; Ge H; Huo G; Zhang L; Chen N; Zhai X; Hong Y; Wang L; Wang Z; Shi W; Mao Y; Yu J; Ke Y; Xia G
    Eur J Med Chem; 2020 May; 193():112239. PubMed ID: 32200202
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors.
    Cherukupalli S; Chandrasekaran B; Kryštof V; Aleti RR; Sayyad N; Merugu SR; Kushwaha ND; Karpoormath R
    Bioorg Chem; 2018 Sep; 79():46-59. PubMed ID: 29753773
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.
    Bussenius J; Anand NK; Blazey CM; Bowles OJ; Bannen LC; Chan DS; Chen B; Co EW; Costanzo S; DeFina SC; Dubenko L; Engst S; Franzini M; Huang P; Jammalamadaka V; Khoury RG; Kim MH; Klein RR; Laird D; Le DT; Mac MB; Matthews DJ; Markby D; Miller N; Nuss JM; Parks JJ; Tsang TH; Tsuhako AL; Wang Y; Xu W; Rice KD
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2283-6. PubMed ID: 22342124
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
    Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
    ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    Shallal HM; Russu WA
    Eur J Med Chem; 2011 Jun; 46(6):2043-57. PubMed ID: 21429632
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment.
    Cui Z; Li X; Li L; Zhang B; Gao C; Chen Y; Tan C; Liu H; Xie W; Yang T; Jiang Y
    Bioorg Med Chem; 2016 Jan; 24(2):261-9. PubMed ID: 26707846
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
    Hossam M; Lasheen DS; Ismail NSM; Esmat A; Mansour AM; Singab ANB; Abouzid KAM
    Eur J Med Chem; 2018 Jan; 144():330-348. PubMed ID: 29275232
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery of a PROTAC targeting ALK with in vivo activity.
    Yan G; Zhong X; Yue L; Pu C; Shan H; Lan S; Zhou M; Hou X; Yang J; Li R
    Eur J Med Chem; 2021 Feb; 212():113150. PubMed ID: 33453602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
    Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
    Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity.
    Li J; Hu H; Lang Q; Zhang H; Huang Q; Wu Y; Yu L
    Eur J Med Chem; 2013 Jul; 65():151-7. PubMed ID: 23707920
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton's tyrosine kinase.
    Zhang D; Xu G; Zhao J; Wang Y; Wu X; He X; Li W; Zhang S; Yang S; Ma C; Jiang Y; Ding Q
    Eur J Med Chem; 2021 Dec; 225():113724. PubMed ID: 34391034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.